Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03056014 · ClinicalTrials.gov registry record · Early Phase 1
Antioxidant Use in Diabetes to Reduce Oxidative Stress
A Early Phase 1 study, sponsored by University of Maryland, Baltimore.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 8
- Enrollment target
NCT03056014 is a Early Phase 1 study that was terminated before completion, run by University of Maryland, Baltimore. The registered enrollment target is 8 participants.
The verdict
NCT03056014, a Early Phase 1 study, was terminated before completion, sponsored by University of Maryland, Baltimore.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
Dietary supplementation with antioxidant vitamins, such as Vitamin C and Vitamin E, reduces malformation rates in embryos of diabetic animals. However, human trials exploring the benefits of these antioxidant vitamins have produced unsatisfactory results in trials designed to alleviating diabetic retinopathy, cardiovascular disease, and preeclampsia in pregnancies. The investigators hypothesize that more potent, and better-targeted antioxidants, such as N-acetylcysteine (NAC) and Polyunsaturated Fatty Acids(PUFA), will be successful in preventing birth defects in the offspring of women with diabetes.
Interventions
- DIETARY_SUPPLEMENT Placebo
- DRUG N-acetyl cysteine
- DIETARY_SUPPLEMENT omega 6 Fish oil ( PUFA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2018-11-01 |
| Est. Completion | 2020-03-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03056014
The ClinicalTrials.gov registry entry for NCT03056014 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03056014 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03056014 about?
NCT03056014 is a clinical study titled "Antioxidant Use in Diabetes to Reduce Oxidative Stress". Dietary supplementation with antioxidant vitamins, such as Vitamin C and Vitamin E, reduces malformation rates in embryos of diabetic animals. However, human trials exploring the benefits of these antioxidant vitamins have produced unsatisfactory results in trials designed to alleviating diabetic re...
What is the current status of trial NCT03056014?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 8 participants. The study started on 2018-11-01. Estimated completion is 2020-03-12.
What interventions are being tested in trial NCT03056014?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), N-acetyl cysteine (DRUG), omega 6 Fish oil ( PUFA) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03056014?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.